Crossmark

Effects of adding a neurokinin-1 receptor antagonist to 5 mg olanzapine, a 5-hydroxytryptamine-3 receptor antagonist, and dexamethasone for preventing carboplatin-induced nausea and vomiting: a propensity score-matched analysis

Crossref DOI link: https://doi.org/10.1186/s12885-022-09392-9

Published Online: 2022-03-23

Published Print: 2022-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Yamamoto, Senri

Iihara, Hirotoshi

Uozumi, Ryuji

Kawazoe, Hitoshi

Tanaka, Kazuki

Fujita, Yukiyoshi

Abe, Masakazu

Imai, Hisao

Karayama, Masato

Hayasaki, Yoh

Hirose, Chiemi

Suda, Takafumi

Nakamura, Kazuto

Suzuki, Akio

Ohno, Yasushi

Morishige, Ken-ichirou

Inui, Naoki
License Information

Text and Data Mining valid from 2022-03-23

Version of Record valid from 2022-03-23
More Information

Article History

Received: 28 October 2021

Accepted: 10 March 2022

First Online: 23 March 2022

Declarations

:

: Study 1 was approved by the Medical Review Board of the Hamamatsu University Graduate School of Medicine (16–296). Written informed consent was obtained from all patients. Study 1 was an opt-out study for the secondary use of data with approval (20–335). Studies 2 and 3 were approved by the Medical Review Board of Gifu University Graduate School of Medicine (30–002, 2018–19). Written informed consent was obtained from all patients. In studies 2 and 3, written informed consent was obtained for the secondary use of data. These studies were conducted in accordance with the Declaration of Helsinki and ethical guidelines for clinical studies.

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below